N@N

Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results

_{//health-fitness.news-articles.net/content/2013/ .. rter-and-fiscal-year-2012-financial-results.html}
^{Published in Health and Fitness on Thursday, February 7th 2013 at 5:16 GMT by Market Wire}  

Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth... -- JERSEY CITY, N.J., Feb. 7, 2013 /PRNewswire/ --

[ ]

[ Download image ]

JERSEY CITY, N.J., Feb. 7, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: [ OPTR ]) today announced it will report fourth quarter and fiscal year 2012 financial results after the NASDAQ Global Market closes on February 28. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the fourth quarter as well as provide a corporate update.

(Logo:  [ http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ])

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at [ www.optimerpharma.com ], where it will be archived for 30 days following the call.  

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society.  Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada.  Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™.  The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at [ http://www.optimerpharma.com ].

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey , VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark , Senior Vice President
619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.